electroCore,

electroCore, Debt/EBITDA

The Total Debt to EBITDA Ratio of electroCore, (ECOR) as of Oct 18, 2026 is -0.69. In the previous year, Total Debt to EBITDA Ratio was -0.34 — a change of 102.25% (lower).

Debt/EBITDA

-0.69

YoY

102.25%

Last updated:

Total Debt to EBITDA Ratio of electroCore, is 2025 -0.69 . Total Debt to EBITDA Ratio of electroCore, was 2024 -0.34 . It decreases by 102.25% lower compared to the previous year.

The electroCore, Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2016
-0.49 USD
Jan 1, 2019
-0.04 USD
Jan 1, 2020
-0.11 USD
Jan 1, 2021
-0.04 USD
Jan 1, 2022
-0.03 USD
Jan 1, 2023
-0.03 USD
Jan 1, 2024
-0.34 USD
Jan 1, 2025
-0.69 USD
The electroCore, Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.69+102.25%
-0.34+921.59%
-0.03+8.93%
-0.03-19.52%
-0.04-66.79%
-0.11+161.06%
-0.04-91.04%
-0.49—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

electroCore, Stock analysis

What does electroCore, do? electroCore, Inc. is a medical device company based in Basking Ridge, New Jersey, operating in the Health Care sector. The company focuses on non-invasive vagus nerve stimulation (nVNS) therapy, offering a hand-held device called gammaCore. This device provides non-drug treatment for adults experiencing episodic cluster and migraine pain. electroCore's technology targets primary headaches, including migraine and cluster headache, as well as related chronic conditions such as gastric motility disorders, psychiatric issues, sleep disorders, and pain disorders. The company went public via an IPO on June 22, 2018, and currently employs 83 full-time staff. Its headquarters are located in Basking Ridge, and it operates within the Health Care industry. electroCore's primary product, gammaCore, is designed for non-invasive cervical vagus nerve stimulation, aiming to address neurological, psychiatric, gastroenterological, and respiratory conditions. The company's website is https://www.electrocore.com/. electroCore is listed under the ticker ECOR with ISIN US28531P2020. The firm's commercial stage operations emphasize non-invasive therapeutic solutions without pharmaceutical intervention. electroCore, is one of the most popular companies on Eulerpool.

Frequently Asked Questions about electroCore, stock

Total Debt to EBITDA Ratio of electroCore, is -0.69 in 2025.

Total Debt to EBITDA Ratio of electroCore, changed from -0.34 to -0.69, representing a 102.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio electroCore, since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's electroCore, with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — electroCore,

All Key Metrics — electroCore,